贝那普利联合洛伐他汀对高血压合并冠心病患者临床疗效影响

Effect of benazepril combined with lovastatin in treatment of hypertensive patients with coronary heart disease

目的观察贝那普利联合洛伐他汀对高血压合并冠心病患者血脂及临床疗效影响。方法选择68例高血压合并冠心病患者,随机分为观察组与对照组,每组各34例。对照组患者给予基础治疗,口服盐酸贝那普利片;观察组患者在基础治疗的基础上同时服用洛伐他汀胶囊。治疗12个月,观察记录2组患者的疗效和不良反应。结果观察组总有效率（94.12%）显著优于对照组（76.47%）,（χ~2=4.22,P〈0.05）;治疗后,2组患者收缩压和舒张压均显著下降（P〈0.05）,其中观察组下降程度较对照组显著（P〈0.05）;治疗后,2组低密度脂蛋白胆固醇（low density lipoprotein cholesterol,LDL-C）、胆固醇（cholesterol,TC）、甘油三酯（triglyceride,TG）显著降低（P〈0.05）,高密度脂蛋白胆固醇（high density lipoprotein cholesterol,HDL-C）显著升高（P〈0.05）,其中观察组改善程度较对照组显著（P〈0.05）。2组均无严重不良反应。结论贝那普利联合洛伐他汀治疗高血压合并冠心病临床疗效显著,可以有效地降低血压、调节血脂,且无明显不良反应。

Objective To observe the effect of benazepril combined with lovastatin in treatment of hypertensive patients with coronary heart disease. Methods 68 hypertensive patients with coronary heart disease were randomly divided into observation group and control group,34 cases in each group. Control group patients were given basic treatment,oral benazepril hydrochloride tablets; observation group patients based on primary treatment was taken lovastatin capsule. For 12 months,the efficacy and adverse reactions of the two groups were observed and recorded. Results Observation group total effective rate（ 94. 12%） was significantly better than the control group（ 76. 47%）,（ χ~2= 4. 22,P〈0. 05）. After treatment,two groups of patients with systolic blood pressure and diastolic blood pressure decreased significantly（ P〈0. 05）,the observation group than the control group declined significantly（ P〈0. 05）. After treatment,LDL-C,TC,TG decreased significantly（ P〈0. 05）,HDL-C increased significantly（ P〈0. 05）.Two groups had no serious adverse reactions. Conclusion Benazepril combined with lovastatin in treatment of hypertensive patients with coronary heart disease has good clinical effect,can effectively reduce blood pressure,regulate blood lipid,and with no obvious adverse reactions.